Asia stocks surge as tech extends rebound, Dec rate cut bets grow
10x Genomics Inc (TXG) stock reached a new 52-week high, closing at 17.26 USD, just a penny above its 52-week high of 17.25 USD. This milestone reflects a significant improvement in the company's market performance, with the stock up 11.31% in just the past week and an impressive 73.89% over the last six months. According to InvestingPro data, the stock's 1-year return actually stands at -2.49%, though recent momentum has been strongly positive. The recent high suggests that 10x Genomics is gaining momentum, potentially driven by advancements in its genomic analysis technologies and an expanding market presence. The company maintains a healthy financial position with a current ratio of 4.48 and more cash than debt on its balance sheet, earning a "GOOD" overall financial health score from InvestingPro. However, investors should note the company remains unprofitable over the last twelve months. Analysts will be watching closely when 10x Genomics reports its next earnings on February 18, 2026, to see if the company can maintain this upward trajectory and move toward profitability.InvestingPro has identified 10+ additional tips for TXG investors, available with a subscription along with comprehensive Pro Research Reports that transform complex Wall Street data into clear, actionable intelligence.
In other recent news, 10x Genomics reported a significant earnings surprise for the second quarter of 2025, posting an earnings per share of $0.28, which exceeded the forecast of -$0.37. The company's revenue for the quarter reached $173 million, surpassing expectations by 24.03%. In addition to its financial performance, 10x Genomics launched a new version of its Chromium Flex assay, designed to enhance scalability and accessibility for large-scale research projects. This updated assay allows researchers to analyze up to 384 samples and 100 million cells per week.
Furthermore, 10x Genomics announced a collaboration with AI company Anthropic to integrate its analysis tools into Anthropic's Claude for Life Sciences platform. This partnership aims to simplify complex biological analyses by allowing researchers to perform tasks through natural language conversations. Piper Sandler initiated coverage on 10x Genomics with a Neutral rating, highlighting the company's leading position in the single cell market. These developments showcase 10x Genomics' ongoing efforts to enhance its technological offerings and expand its market presence.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.